Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) dropped 8.5% during trading on Thursday . The stock traded as low as $1.18 and last traded at $1.19. Approximately 753,183 shares changed hands during trading, an increase of 143% from the average daily volume of 309,784 shares. The stock had previously closed at $1.30.
Analysts Set New Price Targets
Separately, HC Wainwright started coverage on Cardiol Therapeutics in a research note on Monday, June 2nd. They set a "buy" rating and a $9.00 price objective for the company.
Read Our Latest Analysis on Cardiol Therapeutics
Cardiol Therapeutics Trading Up 2.5%
The company has a quick ratio of 3.26, a current ratio of 3.26 and a debt-to-equity ratio of 0.01. The stock has a market cap of $100.83 million, a price-to-earnings ratio of -3.59 and a beta of 1.04. The business's 50 day simple moving average is $1.30 and its 200 day simple moving average is $1.21.
Hedge Funds Weigh In On Cardiol Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. PVG Asset Management Corp purchased a new position in shares of Cardiol Therapeutics in the fourth quarter worth about $624,000. Envestnet Asset Management Inc. purchased a new stake in Cardiol Therapeutics in the fourth quarter valued at approximately $398,000. Tejara Capital Ltd raised its stake in shares of Cardiol Therapeutics by 2.6% during the first quarter. Tejara Capital Ltd now owns 3,194,990 shares of the company's stock worth $3,099,000 after purchasing an additional 79,553 shares during the last quarter. Virtu Financial LLC purchased a new position in Cardiol Therapeutics in the fourth quarter valued at about $61,000. Finally, Cetera Investment Advisers bought a new stake in shares of Cardiol Therapeutics during the 4th quarter worth about $56,000. Hedge funds and other institutional investors own 12.49% of the company's stock.
Cardiol Therapeutics Company Profile
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Further Reading
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
